3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
13
Neoplasms
8
Breast Neoplasms
7
Neoplasm Metastasis
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Adult
1
Solid Tumor
1
Sarcoma, Ewing
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Ovarian Diseases
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm, Residual
1
Melanoma
1
Lung Neoplasms
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
HER2-negative Metastatic Breast Cancer
1
Gonadal Disorders
1
Genital Neoplasms, Male
1
Genital Neoplasms, Female
1
Genital Diseases, Male
1
Genital Diseases, Female
1
Interventions
Cyclophosphamide
7
fludarabine phosphate
6
fludarabine
5
Immunotherapy, Adoptive
3
blinatumomab
2
Cytarabine
2
Azacitidine
2
AP 1903 reagent
2
venetoclax
1
tisagenlecleucel
1
ruxolitinib
1
relugolix
1
pulrodemstat besilate
1
niraparib
1
nilotinib
1
enzalutamide
1
Whole-Body Irradiation
1
Tyrosine Kinase Inhibitors
1
Rituximab
1
Radiotherapy
1
NKTR-255
1
Melphalan
1
Injections
1
Imatinib Mesylate
1
GNKG168
1
Dasatinib
1
Cetuximab
1
CTL019 chimeric antigen receptor
1
CD3 Complex
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasm, Residual
×
niraparib
×
Clear all
NCT03945721
2025-09-29
UNITY
Massachusetts General Hospital
Phase 1
Active not recruiting
21 enrolled